Why this became a focus of concern
In 2023, the European Medicines Agency received reports of suicidal thoughts and self-injury associated with liraglutide and semaglutide, prompting a formal safety review. According to PubMed, a subsequent analysis of the FDA's Adverse Event Reporting System (FAERS) database found disproportionate reporting of suicidal ideation and "depression/suicidal" reports specifically for semaglutide and liraglutide compared with other diabetes medications — but critically, no disproportionate reporting of actual suicidal behavior, suicide attempts, or completed suicide for any FDA-approved GLP-1 medication (McIntyre et al., Expert Opinion on Drug Safety, 2023, DOI (external link)). The authors explicitly concluded that, using standard criteria for evaluating causality, no causal link between GLP-1 medications and suicidality was established by this data.
How to interpret this
Adverse event reporting databases like FAERS capture reports, not confirmed causation — they're a signal-detection tool, not proof of a drug effect, and are subject to reporting bias (a public safety concern can itself increase reporting rates, for example). The distinction the researchers drew — increased ideation and depression reports without increased suicidal behavior or completed suicide — is an important nuance rather than a dismissal of the concern entirely.
Where anhedonia fits in
Separate from the suicidality-specific research, our glossary entry on anhedonia covers a related but distinct concern: some patients report a general blunting of pleasure, including but not limited to food, potentially connected to GLP-1 medications' known effects on brain dopamine and reward pathways (see our guide on suppression, satiation, and satiety for the appetite-specific mechanism). This is a newer, less thoroughly studied area than the suicidality question, and remains something researchers are actively working to characterize.